<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03680794</url>
  </required_header>
  <id_info>
    <org_study_id>PA18053</org_study_id>
    <nct_id>NCT03680794</nct_id>
  </id_info>
  <brief_title>Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies</brief_title>
  <official_title>sCD160 in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CD160 represents a new angiogenic factor as its specific engagement by an agonist monoclonal&#xD;
      antibody directed against human CD160 reduced angiogenesis of endothelial cells with a&#xD;
      distinct mechanism from current angiogenic therapies that target the VEGF/VEGF-R pathway. A&#xD;
      soluble form of CD160, sCD160, has been found to be highly expressed in the vitreous and the&#xD;
      sera of patients with severe diabetic retinopathies, and can now be dosed with help of an&#xD;
      ELISA test.&#xD;
&#xD;
      The investigators aim to evaluate the association between ischaemic retinopathies (patients&#xD;
      with or without) and sCD160 concentrations in the vitreous, the aqueous humour and the serum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      120 patients enrolled for ophthalmic surgery (cataract or posterior segment surgery&#xD;
      (epiretinal membrane, macular hole, vitrectomy)) will be recruited in the Department of&#xD;
      Ophthalmology, Robert Debr√© Hospital, Reims, France.&#xD;
&#xD;
      Each patient will benefit a complete ophthalmologic examination, and either an aqueous&#xD;
      sampling (cataract) or a vitreous sampling (posterior segment) along with a serum sampling at&#xD;
      the beginning of the surgery. ELISA test will be performed on vitreous or aqueous samples in&#xD;
      triplicates. Luminex will be performed on vitreous samples in order to determine the&#xD;
      concentrations of several ischemia biomarkers (VEGF, PlGF, Platelet-derived growth factor&#xD;
      (PDGF-B), SDF-1, Angpt2, InterIeukin IL-6, IL-8, CD105, Monocyte chemoattractant protein 1&#xD;
      (MCP-1), IL-10, interferon-inducible protein-10 ( IP-10), IL-1B and CD106, RAGE).&#xD;
&#xD;
      Primary objective is:&#xD;
&#xD;
      - Evaluation of the association between ischaemic retinopathies (patients with or without)&#xD;
      and sCD160 concentrations of the vitreous or the aqueous humours.&#xD;
&#xD;
      Secondary objectives are:&#xD;
&#xD;
        -  Evaluation of the association between diabetic retinopathies (patients with or without)&#xD;
           and sCD160 concentrations of the vitreous, the aqueous humours and the sera.&#xD;
&#xD;
        -  Evaluation of the association between several vitreous biomarkers of ischaemia and&#xD;
           sCD160 concentrations of the vitreous and the sera.&#xD;
&#xD;
        -  Evaluation of the association between sCD160 concentrations in the vitreous and the&#xD;
           sera.&#xD;
&#xD;
        -  Evaluation of the association between sCD160 concentration in the aqueous humours and&#xD;
           the sera.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sCD160 concentration in the vitreous humor</measure>
    <time_frame>Day 0</time_frame>
    <description>ELISA test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sCD160 concentration in the aqueous humor</measure>
    <time_frame>Day 0</time_frame>
    <description>ELISA test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sCD160 concentration in the serum</measure>
    <time_frame>Day 0</time_frame>
    <description>ELISA test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic retinopathy severity</measure>
    <time_frame>Day 0</time_frame>
    <description>Angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular endothelial growth factor (VEGF)</measure>
    <time_frame>Day 0</time_frame>
    <description>LUMINEX test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placenta Growth Factor-1(PlGF)</measure>
    <time_frame>Day 0</time_frame>
    <description>LUMINEX test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stromal cell-derived factor 1 (SDF-1)</measure>
    <time_frame>Day 0</time_frame>
    <description>LUMINEX test</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Patients with ophthalmic surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sampling of ophthalmic liquid</intervention_name>
    <description>aqueous sampling for patients with cataract surgery or vitreous sampling for patients with posterior segment surgery</description>
    <arm_group_label>Patients with ophthalmic surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        inclusion criteria :&#xD;
&#xD;
          -  over 18 years old&#xD;
&#xD;
          -  with social security affiliation&#xD;
&#xD;
          -  willing to participate this study non-inclusion criteria :&#xD;
&#xD;
          -  any prior (3 months) or concomitant treatment with anti-VEGF therapy, corticosteroids,&#xD;
             or immunosuppressive agents&#xD;
&#xD;
          -  any history of previous vitreoretinal surgery, ocular tumor, severe ocular trauma,&#xD;
             severe intraocular, periocular infection, inflammation, or radiation&#xD;
&#xD;
          -  any serious allergy to the fluorescein sodium for injection in angiography&#xD;
&#xD;
          -  any history of previous systemic anti-VEGF treatment&#xD;
&#xD;
          -  any history of inflammatory or auto-immune disease&#xD;
&#xD;
          -  any active extraocular inflammation or infection in the last 4 weeks before surgery&#xD;
             exclusion criteria :&#xD;
&#xD;
          -  Patients with C-reactive protein CRP &gt; 10mg/mL (serum sampling during surgery)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carl ARNDT</last_name>
    <phone>326787090</phone>
    <phone_ext>0033</phone_ext>
    <email>carndt@chu-reims.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien JOLLY</last_name>
      <phone>326788472</phone>
      <phone_ext>33</phone_ext>
      <email>djolly@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

